Navigation Links
SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
Date:4/24/2013

SAN DIEGO, April 24, 2013 /PRNewswire/ -- Senomyx, Inc. (NASDAQ: SNMX), a  company using proprietary taste science technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Kent Snyder , the Company's Chief Executive Officer, and John Poyhonen , President and Chief Operating Officer, will present an overview of the Company's technology and programs on Wednesday, May 1, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) during the 12th Annual Needham Healthcare Conference.  The conference is taking place at The Westin Grand Central Hotel in New York, NY. During the presentation, Mr. Snyder and Mr. Poyhonen will discuss corporate developments including the Company's pipeline of novel flavor ingredients and its business strategy.

To access the live presentation or a subsequent archived recording, please log onto Senomyx's website at http://www.senomyx.com and click on the "Investor Relations" tab.  The archived webcast will be available for 30 days following the presentation.  Please connect to Senomyx's website prior to the start of the webcast to ensure adequate time to download any software that may be necessary.

About Senomyx, Inc. (www.senomyx.com)

Senomyx is using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients.  These include modifiers of Sweet and Salt flavors as well as Savory Flavors, Bitter Blockers, and Cooling Agents.  The Company is also engaged in a new effort to discover and develop natural high-potency sweeteners.  Under its direct sales initiative, Senomyx is beginning to sell certain of its flavor ingredients to flavor companies for re-sale to their food and beverage company customers.  In addition, Senomyx has collaborative agreements with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx's flavor ingredients.  Senomyx's corporate socially responsible activities are described on the Senomyx Cares blog at http://www.senomyx-csrblog.com/.  For more information, please visit www.senomyx.com.

Contact:
Gwen Rosenberg
Senomyx, Inc.
Vice President, Investor Relations & Corporate Communications
858-646-8369
gwen.rosenberg@senomyx.com


'/>"/>
SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
2. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
3. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
4. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Sigma-Aldrich Corporation Declares Increased Quarterly Dividend; Announces Live Webcasts Of Presentations At Two Upcoming Conferences
7. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
9. BioInformatics LLC Webcast – The Life Science Product Manger’s Toolkit
10. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
11. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The ... asking the Federal Drug Administration (FDA) to consider OA as a serious disease. ... concerned about the growing population of OA patients, many of whom may experience ...
(Date:12/6/2016)... According to a new market research report ... Silicon), Application (Genomics, Proteomics, Capillary Electrophoresis, POC, Clinical, Environmental, Drug Delivery) ... is projected to reach USD 8.78 Billion by 2021 from USD ... forecast period (2016 to 2021). Continue ... ...
(Date:12/6/2016)... ... December 06, 2016 , ... ProMIS ... of precision treatments for neurodegenerative diseases, today announced the validated monoclonal antibody ... direct neurotoxic effect of prion-like forms of Amyloid beta (Aß) in vitro. ...
(Date:12/5/2016)... DENVER, COLORADO (PRWEB) , ... December 05, 2016 ... ... podcast series hosted by one of the nation’s premier cannabis technology and application ... the founder and CEO of Cultivate Colorado. Over the past 30 years, Chip ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , ... today it has seen a third consecutive year of ... sensor technology in 2016 with a 360 percent increase ... year. This increase was driven by sales of its ... robust interest in its technology for hearables for fitness ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):